Pancreatic cancer: Update on immunotherapies and algenpantucel-L

Por McCormick, Kinsey A., Coveler, Andrew L., Rossi, Gabriela R., Vahanian, Nicholas N., Link, Charles, Chiorean, E. Gabriela
Publicado no Hum Vaccin Immunother (2015)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2

Por LoRusso, Patricia, Venkatakrishnan, Karthik, Chiorean, E. Gabriela, Noe, Dennis, Wu, Jing-Tao, Sankoh, Serap, Corvez, Maria, Sausville, Edward A.
Publicado em 2013

Metabolomics Method to Comprehensively Analyze Amino Acids in Different Domains

Por Gu, Haiwei, Du, Jianhai, Neto, Fausto Carnevale, Carroll, Patrick Andrew, Turner, Sally, Chiorean, E. Gabriela, Eisenman, Robert N., Raftery, Daniel
Publicado no Analyst (2015)

Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101

Por Chiorean, E. Gabriela, Ramasubbaiah, Rashmi, Yu, Menggang, Picus, Joel, Bufill, Jose A., Tong, Yan, Coleman, Nicki, Johnston, Erica L., Currie, Colleen, Loehrer, Patrick J.
Publicado em 2012

Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis

Por Gu, Dongsheng, Liu, Hailan, Su, Gloria H., Zhang, Xiaoli, Chin-Sinex, Helen, Hanenberg, Helmut, Mendonca, Marc S., Shannon, Harlan E., Chiorean, E. Gabriela, Xie, Jingwu
Publicado em 2013

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

Por Sweeney, Christopher J., Chiorean, E. Gabriela, Verschraegen, Claire F., Lee, Fa Chyi, Jones, Suzanne, Royce, Melanie, Tye, Lesley, Liau, Katherine F., Bello, Akintunde, Chao, Richard, Burris, Howard A.
Publicado em 2010

Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers

Por Yang, Youyun, Li, Hailan, Li, Zhaomin, Zhao, Zijin, Yip-Schneider, Michelle, Fan, Qipeng, Schmidt, C. Max, Chiorean, E. Gabriela, Xie, Jingwu, Cheng, Liang, Chen, Jey-Hsin, Zhang, Jian-Ting
Publicado em 2011

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

Por Tabernero, Josep, Chawla, Sant P., Kindler, Hedy, Reckamp, Karen, Chiorean, E. Gabriela, Azad, Nilofer S., Lockhart, A. Craig, Hsu, Cheng-Pang, Baker, Nigel F., Galimi, Francesco, Beltran, Pedro, Baselga, José
Publicado no Target Oncol (2014)

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

Por Beatty, Gregory L., Torigian, Drew A., Chiorean, E. Gabriela, Saboury, Babak, Brothers, Alex, Alavi, Abass, Troxel, Andrea B., Sun, Weijing, Teitelbaum, Ursina R., Vonderheide, Robert H., O’Dwyer, Peter J.
Publicado em 2013

Contribution of Environment and Genetics to Pancreatic Cancer Susceptibility

Por Hocevar, Barbara A., Kamendulis, Lisa M., Pu, Xinzhu, Perkins, Susan M., Wang, Zheng-Yu, Johnston, Erica L., DeWitt, John M., Li, Lang, Loehrer, Patrick J., Klaunig, James E., Chiorean, E. Gabriela
Publicado em 2014

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Can...

Por Tabernero, Josep, Chiorean, E. Gabriela, Infante, Jeffrey R., Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin, Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David, Penenberg, Darryl N., Romano, Alfredo, Ferrara, Stefano, Von Hoff, Daniel D.
Publicado no Oncologist (2015)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Por Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Ma, Wen Wee, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Li, Jack Shiansong, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Publicado no Br J Cancer (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Por Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Wee Ma, Wen, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Shiansong Li, Jack, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Publicado no Br J Cancer (2016)

An Open Label Phase 1b Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Por Gordon, Michael S., Robert, Francisco, Matei, Daniela, Mendelson, David S., Goldman, Jonathan W., Chiorean, E. Gabriela, Strother, Robert M., Seon, Ben K., Figg, William D., Peer, Cody J., Alvarez, Delia, Adams, Bonne J., Theuer, Charles P., Rosen, Lee S.
Publicado no Clin Cancer Res (2014)

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G(1) Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor...

Por Spratlin, Jennifer L., Cohen, Roger B., Eadens, Matthew, Gore, Lia, Camidge, D. Ross, Diab, Sami, Leong, Stephen, O'Bryant, Cindy, Chow, Laura Q.M., Serkova, Natalie J., Meropol, Neal J., Lewis, Nancy L., Chiorean, E. Gabriela, Fox, Floyd, Youssoufian, Hagop, Rowinsky, Eric K., Eckhardt, S. Gail
Publicado em 2010

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Por Borad, Mitesh J., Reddy, Shantan G., Bahary, Nathan, Uronis, Hope E., Sigal, Darren, Cohn, Allen L., Schelman, William R., Stephenson, Joe, Chiorean, E. Gabriela, Rosen, Peter J., Ulrich, Brian, Dragovich, Tomislav, Del Prete, Salvatore A., Rarick, Mark, Eng, Clarence, Kroll, Stew, Ryan, David P.
Publicado no J Clin Oncol (2015)

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Por Von Hoff, Daniel D., Ervin, Thomas, Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A., Ma, Wen Wee, Saleh, Mansoor N., Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K., Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F.
Publicado no N Engl J Med (2013)